[
  {
    "ts": "2025-12-15T00:18:23+00:00",
    "headline": "Why IDEAYA Biosciences (IDYA) Is Down 5.2% After Completing Enrollment In Pivotal Uveal Melanoma Trial",
    "summary": "IDEAYA Biosciences recently completed full enrollment of 435 patients in its registration-enabling Phase 2/3 OptimUM-02 trial testing oral PKC inhibitor darovasertib plus Pfizer’s crizotinib in first-line HLA*A2-negative metastatic uveal melanoma, while also advancing IDE034 and IDE574 into early-stage clinical development. This milestone underscores IDEAYA’s push to convert promising early uveal melanoma data and multiple FDA designations for darovasertib into a potential accelerated...",
    "url": "https://finance.yahoo.com/news/why-ideaya-biosciences-idya-down-001823496.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "675076f1-f0df-3014-8b45-b2d1f950cc2c",
      "content": {
        "id": "675076f1-f0df-3014-8b45-b2d1f950cc2c",
        "contentType": "STORY",
        "title": "Why IDEAYA Biosciences (IDYA) Is Down 5.2% After Completing Enrollment In Pivotal Uveal Melanoma Trial",
        "description": "",
        "summary": "IDEAYA Biosciences recently completed full enrollment of 435 patients in its registration-enabling Phase 2/3 OptimUM-02 trial testing oral PKC inhibitor darovasertib plus Pfizer’s crizotinib in first-line HLA*A2-negative metastatic uveal melanoma, while also advancing IDE034 and IDE574 into early-stage clinical development. This milestone underscores IDEAYA’s push to convert promising early uveal melanoma data and multiple FDA designations for darovasertib into a potential accelerated...",
        "pubDate": "2025-12-15T00:18:23Z",
        "displayTime": "2025-12-15T00:18:23Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/4d522452d0da08d8412701a84270533b",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/FqD7IP1YjoMtOLiC1foWBQ--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/4d522452d0da08d8412701a84270533b.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/DnvRJ7zmyZqa8oFdfcLgCg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/4d522452d0da08d8412701a84270533b.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/why-ideaya-biosciences-idya-down-001823496.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/why-ideaya-biosciences-idya-down-001823496.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "IDYA"
            },
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]